Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

BioMarin to start phase III program for PEG-PAL in 2013

Sep. 28, 2012

Sanofi discloses several new agents for diabetes

Sep. 28, 2012

EE-TP shows promise for the treatment of MNGIE

Sep. 28, 2012

Minicircle plasmid DNA vector successfully treats liver disease in mice

Sep. 27, 2012

Novartis obtains positive CHMP opinions for Galvus and Eucreas

Sep. 26, 2012

Chinese group synthesizes new SGLT2 inhibitors

Sep. 26, 2012

Benefits seen with rhLAMAN in patients with alpha-mannosidosis

Sep. 26, 2012

CHMP recommends expanded approval of Trajenta tablets

Sep. 25, 2012

VIVUS anticipates CHMP opinion on Qsiva MAA

Sep. 25, 2012

Eliglustat efficacy maintained for 4 years in patients with Gaucher's disease

Sep. 25, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...